JPS60132920A - ガングリオシドおよび誘導体を含む吸入用製剤 - Google Patents
ガングリオシドおよび誘導体を含む吸入用製剤Info
- Publication number
- JPS60132920A JPS60132920A JP59235934A JP23593484A JPS60132920A JP S60132920 A JPS60132920 A JP S60132920A JP 59235934 A JP59235934 A JP 59235934A JP 23593484 A JP23593484 A JP 23593484A JP S60132920 A JPS60132920 A JP S60132920A
- Authority
- JP
- Japan
- Prior art keywords
- ganglioside
- moiety
- acid
- pharmaceutically acceptable
- kit according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000002270 gangliosides Chemical class 0.000 title description 56
- 238000000034 method Methods 0.000 title description 32
- 239000003814 drug Substances 0.000 title description 4
- 239000000203 mixture Substances 0.000 claims description 69
- -1 ganglioside compound Chemical class 0.000 claims description 39
- 150000002148 esters Chemical group 0.000 claims description 35
- 150000001875 compounds Chemical class 0.000 claims description 26
- 150000001720 carbohydrates Chemical group 0.000 claims description 20
- 239000002253 acid Substances 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 14
- 239000007921 spray Substances 0.000 claims description 13
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 10
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 9
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 8
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 8
- 229940106189 ceramide Drugs 0.000 claims description 8
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 8
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 8
- 229940124630 bronchodilator Drugs 0.000 claims description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 7
- 239000003380 propellant Substances 0.000 claims description 7
- 235000014633 carbohydrates Nutrition 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 125000000686 lactone group Chemical group 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims description 4
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 4
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 claims description 4
- SUHQNCLNRUAGOO-UHFFFAOYSA-N N-glycoloyl-neuraminic acid Natural products OCC(O)C(O)C(O)C(NC(=O)CO)C(O)CC(=O)C(O)=O SUHQNCLNRUAGOO-UHFFFAOYSA-N 0.000 claims description 4
- FDJKUWYYUZCUJX-UHFFFAOYSA-N N-glycolyl-beta-neuraminic acid Natural products OCC(O)C(O)C1OC(O)(C(O)=O)CC(O)C1NC(=O)CO FDJKUWYYUZCUJX-UHFFFAOYSA-N 0.000 claims description 4
- FDJKUWYYUZCUJX-KVNVFURPSA-N N-glycolylneuraminic acid Chemical compound OC[C@H](O)[C@H](O)[C@@H]1O[C@](O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-KVNVFURPSA-N 0.000 claims description 4
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical group CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 claims 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 230000007883 bronchodilation Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 238000002627 tracheal intubation Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 125000005629 sialic acid group Chemical group 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 159000000000 sodium salts Chemical class 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 5
- WMYNMYVRWWCRPS-UHFFFAOYSA-N ethynoxyethane Chemical group CCOC#C WMYNMYVRWWCRPS-UHFFFAOYSA-N 0.000 description 5
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 4
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical group C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 4
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical group CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 244000186140 Asperula odorata Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 235000008526 Galium odoratum Nutrition 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 2
- ZNPNOVHKCAAQCG-UHFFFAOYSA-N 2-chloro-1-methylpyridin-1-ium Chemical class C[N+]1=CC=CC=C1Cl ZNPNOVHKCAAQCG-UHFFFAOYSA-N 0.000 description 2
- HQARDVLSJLCFBA-UHFFFAOYSA-N 4-[(4-aminophenyl)carbamoyl]-1h-imidazole-5-carboxylic acid Chemical compound C1=CC(N)=CC=C1NC(=O)C1=C(C(O)=O)NC=N1 HQARDVLSJLCFBA-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 238000002663 nebulization Methods 0.000 description 2
- 230000008760 nerve sprouting Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical class C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- MWOOKDULMBMMPN-UHFFFAOYSA-N 3-(2-ethyl-1,2-oxazol-2-ium-5-yl)benzenesulfonate Chemical compound O1[N+](CC)=CC=C1C1=CC=CC(S([O-])(=O)=O)=C1 MWOOKDULMBMMPN-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- 108010074725 Alpha,alpha-trehalose phosphorylase Proteins 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 101100264195 Caenorhabditis elegans app-1 gene Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 229920001890 Novodur Polymers 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 150000002339 glycosphingolipids Chemical class 0.000 description 1
- 125000000625 hexosyl group Chemical group 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229960001317 isoprenaline Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- DUZPCMXUYQIWCZ-UHFFFAOYSA-N n'-(3-phenylpropyl)methanediimine Chemical compound N=C=NCCCC1=CC=CC=C1 DUZPCMXUYQIWCZ-UHFFFAOYSA-N 0.000 description 1
- VJMRKWPMFQGIPI-UHFFFAOYSA-N n-(2-hydroxyethyl)-5-(hydroxymethyl)-3-methyl-1-[2-[[3-(trifluoromethyl)phenyl]methyl]-1-benzothiophen-7-yl]pyrazole-4-carboxamide Chemical compound OCC1=C(C(=O)NCCO)C(C)=NN1C1=CC=CC2=C1SC(CC=1C=C(C=CC=1)C(F)(F)F)=C2 VJMRKWPMFQGIPI-UHFFFAOYSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- LUKVNUBQLMJEOI-UHFFFAOYSA-N n-benzyl-n'-propan-2-ylmethanediimine Chemical compound CC(C)N=C=NCC1=CC=CC=C1 LUKVNUBQLMJEOI-UHFFFAOYSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000011356 non-aqueous organic solvent Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000009527 percussion Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000004940 physical analysis method Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 125000002544 sphingolipid group Chemical group 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000018405 transmission of nerve impulse Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
- C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT8349288A IT1212896B (it) | 1983-11-08 | 1983-11-08 | Metodo di somministrazione per via inalatoria di gangliosidi e derivati, e composizioni farmaceutiche relative |
| IT49288A/83 | 1983-11-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60132920A true JPS60132920A (ja) | 1985-07-16 |
| JPH0211570B2 JPH0211570B2 (es) | 1990-03-14 |
Family
ID=11270228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59235934A Granted JPS60132920A (ja) | 1983-11-08 | 1984-11-07 | ガングリオシドおよび誘導体を含む吸入用製剤 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US4639437A (es) |
| EP (1) | EP0145209B1 (es) |
| JP (1) | JPS60132920A (es) |
| KR (1) | KR850003503A (es) |
| AT (1) | ATE47035T1 (es) |
| AU (1) | AU569920B2 (es) |
| BE (1) | BE900994A (es) |
| CH (1) | CH662278A5 (es) |
| DE (1) | DE3480053D1 (es) |
| DK (1) | DK160129C (es) |
| ES (1) | ES8608532A1 (es) |
| FR (1) | FR2554346B1 (es) |
| GR (1) | GR80853B (es) |
| IL (1) | IL73292A (es) |
| IN (1) | IN163563B (es) |
| IT (1) | IT1212896B (es) |
| LU (1) | LU85633A1 (es) |
| MX (1) | MX163574B (es) |
| NO (1) | NO844443L (es) |
| NZ (1) | NZ209974A (es) |
| PT (1) | PT79466B (es) |
| ZA (1) | ZA848541B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1177863B (it) * | 1984-07-03 | 1987-08-26 | Fidia Farmaceutici | Una miscela gangliosidica come agente terapeutico capare di eliminare il dolore nele neuropatie periferiche |
| JPS6368526A (ja) * | 1986-09-11 | 1988-03-28 | Mect Corp | シアリルグリセライドからなる神経障害疾患治療剤 |
| US4816450A (en) * | 1986-09-15 | 1989-03-28 | Duke University | Inhibition of protein kinase C by long-chain bases |
| US4937232A (en) * | 1986-09-15 | 1990-06-26 | Duke University | Inhibition of protein kinase C by long-chain bases |
| IT1212041B (it) * | 1987-11-02 | 1989-11-08 | Fidia Farmaceutici | Gangliosidi esteri interni come agenti terapeutici capaci di eliminare il dolore nelle neuropatie periferiche |
| US5073543A (en) * | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| US6407061B1 (en) | 1989-12-05 | 2002-06-18 | Chiron Corporation | Method for administering insulin-like growth factor to the brain |
| US5624898A (en) | 1989-12-05 | 1997-04-29 | Ramsey Foundation | Method for administering neurologic agents to the brain |
| AU6909091A (en) * | 1989-12-05 | 1991-06-26 | Ramsey Foundation | Neurologic agents for nasal administration to the brain |
| IT1249034B (it) * | 1990-06-29 | 1995-02-11 | Fidia Spa | Impiego del monosialoganglioside gm1 e del suo derivato estere interno per impedire l'instaurarsi della tolleranza nell'uomo all'effetto analgesico della morfina e analoghi |
| WO1992017189A1 (en) * | 1991-03-29 | 1992-10-15 | The Regents Of The University Of California | Gangliosides with immunosuppressive activity |
| WO1993002686A1 (en) * | 1991-07-31 | 1993-02-18 | The Regents Of The University Of California | Gangliosides with immunosuppressive ceramide moieties |
| US5567684A (en) * | 1994-09-14 | 1996-10-22 | The Regents Of The University Of California | Synthetic ganglioside derivatives |
| US7273618B2 (en) * | 1998-12-09 | 2007-09-25 | Chiron Corporation | Method for administering agents to the central nervous system |
| AU2002326805B2 (en) | 2001-08-29 | 2009-01-22 | Seneb Biosciences, Inc. | Novel synthetic ganglioside derivatives and compositions thereof |
| NZ542148A (en) | 2003-03-06 | 2008-05-30 | Neose Technologies Inc | Methods and compositions for the enzymatic synthesis of gangliosides |
| CU23317A1 (es) | 2005-07-22 | 2008-10-22 | Ct De Investigacia N Y Desarro | Formulaciones nasales de eporh con bajo contenido de ã cido siã lico para el tratamiento de enfermedades del sistema nervioso central |
| US20120035120A1 (en) | 2009-03-25 | 2012-02-09 | Seneb Biosciences, Inc. | Glycolipids as treatment for disease |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL262354A (es) * | 1960-03-17 | |||
| US3282781A (en) * | 1960-11-25 | 1966-11-01 | Merck & Co Inc | Inhalant compositions |
| US4094968A (en) * | 1972-09-06 | 1978-06-13 | Burroughs Wellcome Co. | Treatment for allergy and method of composition thereof |
| GB1571629A (en) * | 1977-11-30 | 1980-07-16 | Fisons Ltd | Pharmaceutical compositions containing beclomethasone dipropionate |
| US4476119A (en) * | 1981-08-04 | 1984-10-09 | Fidia S.P.A. | Method for preparing ganglioside derivatives and use thereof in pharmaceutical compositions |
-
1983
- 1983-11-08 IT IT8349288A patent/IT1212896B/it active
-
1984
- 1984-04-12 US US06/599,340 patent/US4639437A/en not_active Expired - Fee Related
- 1984-10-23 IL IL73292A patent/IL73292A/xx unknown
- 1984-10-23 DK DK505584A patent/DK160129C/da not_active IP Right Cessation
- 1984-10-24 NZ NZ209974A patent/NZ209974A/en unknown
- 1984-10-26 DE DE8484307403T patent/DE3480053D1/de not_active Expired
- 1984-10-26 AT AT84307403T patent/ATE47035T1/de not_active IP Right Cessation
- 1984-10-26 EP EP84307403A patent/EP0145209B1/en not_active Expired
- 1984-10-26 IN IN750/CAL/84A patent/IN163563B/en unknown
- 1984-10-31 ES ES537300A patent/ES8608532A1/es not_active Expired
- 1984-11-01 ZA ZA848541A patent/ZA848541B/xx unknown
- 1984-11-06 GR GR80853A patent/GR80853B/el unknown
- 1984-11-06 MX MX203300A patent/MX163574B/es unknown
- 1984-11-06 FR FR8416859A patent/FR2554346B1/fr not_active Expired
- 1984-11-07 CH CH5339/84A patent/CH662278A5/fr not_active IP Right Cessation
- 1984-11-07 JP JP59235934A patent/JPS60132920A/ja active Granted
- 1984-11-07 NO NO844443A patent/NO844443L/no unknown
- 1984-11-07 BE BE1/011131A patent/BE900994A/nl not_active IP Right Cessation
- 1984-11-07 AU AU35189/84A patent/AU569920B2/en not_active Ceased
- 1984-11-07 LU LU85633A patent/LU85633A1/fr unknown
- 1984-11-07 PT PT79466A patent/PT79466B/pt not_active IP Right Cessation
- 1984-11-08 KR KR1019840006985A patent/KR850003503A/ko not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL73292A0 (en) | 1985-01-31 |
| DK160129C (da) | 1991-07-01 |
| ES8608532A1 (es) | 1986-07-16 |
| DK160129B (da) | 1991-02-04 |
| EP0145209B1 (en) | 1989-10-11 |
| DK505584D0 (da) | 1984-10-23 |
| ATE47035T1 (de) | 1989-10-15 |
| EP0145209A2 (en) | 1985-06-19 |
| PT79466A (en) | 1984-12-01 |
| NZ209974A (en) | 1987-02-20 |
| AU569920B2 (en) | 1988-02-25 |
| GR80853B (en) | 1985-02-26 |
| BE900994A (nl) | 1985-05-07 |
| CH662278A5 (fr) | 1987-09-30 |
| ES537300A0 (es) | 1986-07-16 |
| IL73292A (en) | 1988-07-31 |
| DE3480053D1 (en) | 1989-11-16 |
| US4639437A (en) | 1987-01-27 |
| IT8349288A0 (it) | 1983-11-08 |
| EP0145209A3 (en) | 1986-11-26 |
| ZA848541B (en) | 1985-06-26 |
| NO844443L (no) | 1985-05-09 |
| AU3518984A (en) | 1985-05-16 |
| JPH0211570B2 (es) | 1990-03-14 |
| LU85633A1 (fr) | 1985-06-04 |
| FR2554346B1 (fr) | 1987-11-20 |
| PT79466B (en) | 1986-12-12 |
| KR850003503A (ko) | 1985-06-20 |
| MX163574B (es) | 1992-06-02 |
| IT1212896B (it) | 1989-11-30 |
| DK505584A (da) | 1985-05-09 |
| IN163563B (es) | 1988-10-08 |
| FR2554346A1 (fr) | 1985-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS60132920A (ja) | ガングリオシドおよび誘導体を含む吸入用製剤 | |
| EP0072722B1 (en) | A method for preparing ganglioside derivatives and use thereof in pharmaceutical compositions | |
| JPH02124830A (ja) | ガングリオシドーリポソームビヒクル中の刺激因子の制御放出製剤 | |
| US4698332A (en) | Expectorant | |
| CN105622673B (zh) | 具有抗癌活性的糖基化四价铂类化合物、制备方法及应用 | |
| EP0067130A2 (en) | An allergen dry powder composition and process for its preparation | |
| EP2199402A1 (en) | Cycloastragenol monoglucoside, preparation, pharmaceutical composition and application thereof | |
| JPS6130521A (ja) | 末梢神経障害の疼痛治療用ガングリオシド混合物 | |
| US4386077A (en) | Pharmaceutical composition for oral administration containing cytidine diphosphocholine | |
| JPH01157995A (ja) | 鎮痛−抗炎症活性を有するガングリオシドの内部エステル | |
| EP0267297B1 (en) | Sialosylcholesterol, process for its preparation, and drug for treating diseases of nervous system | |
| JPH03179000A (ja) | 天然のガングリオシドまたはその誘導体を用いる神経成長因子の生物学的活性の安定化および維持 | |
| CN114042043B (zh) | 一种雷公藤甲素线粒体靶向脂质体及其应用 | |
| KR890004136B1 (ko) | 시 알로실 콜레스테롤 및 그의 제조 방법 및 시알로실 콜레스테롤로 이루어지는 신경성 질환 치료제 | |
| CN1651397B (zh) | 一种含有脂肪酸的薄荷醇衍生物及含有该衍生物的制剂 | |
| CN107922453A (zh) | 作为红血球生成素及红血球生成素受体的正变构调节子以治疗红血球生成素缺乏疾病的新化合物 | |
| CN114344380A (zh) | 一种止喘灵雾化吸入用溶液制剂及其制备方法 | |
| EP1074260B1 (en) | IL-12 Production inhibitor | |
| CA1228295A (en) | Kit or device and method for administering gangliosides and derivatives thereof by inhalation and pharmaceutical composition suitable thereof | |
| Laurenzi et al. | Studies of Mucus Flow in the Mammalian Respiratory Tract: I. The Beneficial Effects of Acetyl Ouabain on Respiratory Tract Mucus Flow | |
| JPH02111785A (ja) | スフインゴ糖脂質 | |
| JPS6075431A (ja) | エリスロマイシンの塩およびそれを有効成分とする抗生−免疫賦活剤 | |
| JPS634557B2 (es) | ||
| WO2000047594A1 (fr) | Nouveau derives d'acide gymnemique, leur procede de preparation et leur application comme medicaments | |
| JP4885989B2 (ja) | ジベレリンの調製および糖尿病での使用 |